Atrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates

MT Newswires Live

02/27

Atrium Therapeutics (RNA) said Friday it has started operations as an independent, publicly traded company with lead precision cardiology candidates ATR 1072 and ATR 1086.

The company also said it has about $270 million in cash and cash equivalents, and two undisclosed research targets.

Atrium said ATR 1072 is currently in preclinical studies for PRKAG2 syndrome, with an investigational new drug filing expected in H2, while ATR 1086 is expected to enter preclinical studies this year for phospholamban cardiomyopathy, with an IND filing targeted in 2027.

Atrium was spun out of Avidity Biosciences as part of Avidity's acquisition by Novartis (NVS). The acquisition was completed Friday, Novartis said.

Shares of Atrium Therapeutics were down 2.7% in recent Friday trading.

Price: 13.79, Change: -0.99, Percent Change: -6.71

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2614850908"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614850908\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614850908?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 23:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614850908","market":"fut","top_or_hot":-1,"title":"Atrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates","media":"MT Newswires Live","content":"<html><body><p> Atrium <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RNA) said Friday it has started operations as an independent, publicly traded company with lead precision cardiology candidates ATR 1072 and ATR 1086.</p><p>The company also said it has about $270 million in cash and cash equivalents, and two undisclosed research targets.</p><p>Atrium said ATR 1072 is currently in preclinical studies for PRKAG2 syndrome, with an investigational new drug filing expected in H2, while ATR 1086 is expected to enter preclinical studies this year for phospholamban cardiomyopathy, with an IND filing targeted in 2027.</p><p>Atrium was spun out of <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a> as part of Avidity's acquisition by Novartis (NVS). The acquisition was completed Friday, Novartis said.</p><p>Shares of Atrium Therapeutics were down 2.7% in recent Friday trading.</p><p>Price: 13.79, Change: -0.99, Percent Change: -6.71</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Atrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAtrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-02-27 23:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Atrium <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RNA) said Friday it has started operations as an independent, publicly traded company with lead precision cardiology candidates ATR 1072 and ATR 1086.</p><p>The company also said it has about $270 million in cash and cash equivalents, and two undisclosed research targets.</p><p>Atrium said ATR 1072 is currently in preclinical studies for PRKAG2 syndrome, with an investigational new drug filing expected in H2, while ATR 1086 is expected to enter preclinical studies this year for phospholamban cardiomyopathy, with an IND filing targeted in 2027.</p><p>Atrium was spun out of <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a> as part of Avidity's acquisition by Novartis (NVS). The acquisition was completed Friday, Novartis said.</p><p>Shares of Atrium Therapeutics were down 2.7% in recent Friday trading.</p><p>Price: 13.79, Change: -0.99, Percent Change: -6.71</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2614850908","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614850908","pubTimestamp":1772206324,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Atrium Therapeutics  said Friday it has started operations as an independent, publicly traded company with lead precision cardiology candidates ATR 1072 and ATR 1086.The company also said it has about $270 million in cash and cash equivalents, and two undisclosed research targets.Atrium said ATR 1072 is currently in preclinical studies for PRKAG2 syndrome, with an investigational new drug filing expected in H2, while ATR 1086 is expected to enter preclinical studies this year for phospholamban cardiomyopathy, with an IND filing targeted in 2027.Atrium was spun out of Avidity Biosciences as part of Avidity's acquisition by Novartis . The acquisition was completed Friday, Novartis said.Shares of Atrium Therapeutics were down 2.7% in recent Friday trading.Price: 13.79, Change: -0.99, Percent Change: -6.71","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4007":"制药","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4539":"次新股","RNA":"Atrium Therapeutics","BK4532":"文艺复兴科技持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4139":"生物科技","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","NVS":"诺华","LENZ":"Therapeutics","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4505":"高瓴资本持仓","BK4578":"CAR-T"},"translate_title":"Atrium Therapeutics开始运营2款精准心脏病学候选药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"NVS":1,"RNA":1},"content_text":"Atrium Therapeutics (RNA) said Friday it has started operations as an independent, publicly traded company with lead precision cardiology candidates ATR 1072 and ATR 1086.The company also said it has about $270 million in cash and cash equivalents, and two undisclosed research targets.Atrium said ATR 1072 is currently in preclinical studies for PRKAG2 syndrome, with an investigational new drug filing expected in H2, while ATR 1086 is expected to enter preclinical studies this year for phospholamban cardiomyopathy, with an IND filing targeted in 2027.Atrium was spun out of Avidity Biosciences as part of Avidity's acquisition by Novartis (NVS). The acquisition was completed Friday, Novartis said.Shares of Atrium Therapeutics were down 2.7% in recent Friday trading.Price: 13.79, Change: -0.99, Percent Change: -6.71","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}